Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors

This study is a very early-stage research project looking into a new medication called BNT314. It's designed for people who have advanced solid tumours, which are cancers that form solid lumps and may have spread to other parts of the body. For these individuals, standard treatments might no longer be proving effective. The main aim of this study is to carefully check the safety of BNT314 when used on its own. It's a 'first-in-human' study, meaning it's one of the first times this medicine is being given to people, so understanding its safety is the top priority.

Researchers will start by giving different groups of patients increasing doses of BNT314. This step, called 'dose escalation', helps them identify the highest dose that patients can take without experiencing too many difficult side effects. This safe dosage is known as the 'Maximum Tolerated Dose'. While the primary focus is on safety, the study will also look for any early signs that BNT314 might be helping to shrink or control the cancer. They will also gather information on how the body handles the medicine and how it affects the cancer cells.

This study is taking place in several medical centres across different countries. Patients will receive BNT314 through a drip (infusion) in regular cycles. The treatment will continue as long as the cancer doesn't get worse, the side effects are manageable, or for up to two years, whichever comes first. The valuable information gathered from this study will help decide if BNT314 should be further developed and tested as a potential new cancer treatment.